Wanwei Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wanwei Cao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Feng Shu
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China
11 shared publications - Guanmin Jiang
Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
11 shared publications - Hao Liu
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China
11 shared publications - Hao Wang
Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
11 shared publications - Hongsheng Wang
Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
11 shared publications - Jiangli Zhou
Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China
11 shared publications
Latest Publications
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The differentially expressed genes in the DU145-shNFIB cells vs DU145-shNC cells was listed in Supplementary Table S3.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The differentially expressed genes in the DU145-shNFIB cells vs DU145-shNC cells was listed in Supplementary Table S3.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
This PDF contais Supplementary Figures 1-4.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
This PDF contais Supplementary Figures 1-4.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The differentially expressed genes in the DU145-shNFIB cells vs DU145-shNC cells was listed in Supplementary Table S3.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The differentially expressed genes in the DU145-shNFIB cells vs DU145-shNC cells was listed in Supplementary Table S3.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
This PDF contais Supplementary Figures 1-4.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
This PDF contais Supplementary Figures 1-4.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1-2 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The sequences of the siRNAs are listed in Supplementary Table S1. And the sequences of the primers, ChIP primers and MeRIP primers used are listed in Supplementary Table S2.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1-2 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The sequences of the siRNAs are listed in Supplementary Table S1. And the sequences of the primers, ChIP primers and MeRIP primers used are listed in Supplementary Table S2.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
Proteins that bind with NFIB rather than IgG, in both NFIB_1 and NFIB_2 samples.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
Proteins that bind with NFIB rather than IgG, in both NFIB_1 and NFIB_2 samples.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1-2 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The sequences of the siRNAs are listed in Supplementary Table S1. And the sequences of the primers, ChIP primers and MeRIP primers used are listed in Supplementary Table S2.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1-2 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The sequences of the siRNAs are listed in Supplementary Table S1. And the sequences of the primers, ChIP primers and MeRIP primers used are listed in Supplementary Table S2.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
Proteins that bind with NFIB rather than IgG, in both NFIB_1 and NFIB_2 samples.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
Proteins that bind with NFIB rather than IgG, in both NFIB_1 and NFIB_2 samples.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Data from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
Data from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
Data from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Data from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The widespread use of androgen receptor (AR) signaling inhibitors has led to an increased incidence of AR-negative castration-resistant prostate cancer (CRPC), limiting effective treatment and patient survival. A more comprehensive understanding of the molecular mechanisms supporting AR-negative CRPC could reveal therapeutic vulnerabilities to improve treatment. This study showed that the transcription factor nuclear factor I/B (NFIB) was upregulated in patient with AR-negative CRPC tumors and cell lines and was positively associated with an epithelial-to-mesenchymal transition (EMT) phenotype. Loss of NFIB inhibited EMT and reduced migration of CRPC cells. NFIB directly bound to gene promoters and regulated the transcription of EMT-related factors E-cadherin (CDH1) and vimentin (VIM), independent of other typical EMT-related transcriptional factors. In vivo data further supported the positive role of NFIB in the metastasis of AR-negative CRPC cells. Moreover, N6-methyladenosine (m6A) modification induced NFIB upregulation in AR-negative CRPC. Mechanistically, the m6A levels of mRNA, including NFIB and its E3 ubiquitin ligase TRIM8, were increased in AR-negative CRPC cells. Elevated m6A methylation of NFIB mRNA recruited YTHDF2 to increase mRNA stability and protein expression. Inversely, the m6A modification of TRIM8 mRNA, induced by ALKBH5 downregulation, decreased its translation and expression, which further promoted NFIB protein stability. Overall, this study reveals that upregulation of NFIB, mediated by m6A modification, triggers EMT and metastasis in AR-negative CRPC. Targeting the m6A/NFIB axis is a potential prevention and treatment strategy for AR-negative CRPC metastasis.Significance:NFIB upregulation mediated by increased m6A levels in AR-negative castration-resistant prostate cancer regulates transcription of EMT-related factors to promote metastasis, providing a potential therapeutic target to improve prostate cancer treatment.
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB
The widespread use of androgen receptor (AR) signaling inhibitors has led to an increased incidence of AR-negative castration-resistant prostate cancer (CRPC), limiting effective treatment and patient survival. A more comprehensive understanding of the molecular mechanisms supporting AR-negative CRPC could reveal therapeutic vulnerabilities to improve treatment. This study showed that the transcription factor nuclear factor I/B (NFIB) was upregulated in patient with AR-negative CRPC tumors and cell lines and was positively associated with an epithelial-to-mesenchymal transition (EMT) phenotype. Loss of NFIB inhibited EMT and reduced migration of CRPC cells. NFIB directly bound to gene promoters and regulated the transcription of EMT-related factors E-cadherin (CDH1) and vimentin (VIM), independent of other typical EMT-related transcriptional factors. In vivo data further supported the positive role of NFIB in the metastasis of AR-negative CRPC cells. Moreover, N6-methyladenosine (m6A) modification induced NFIB upregulation in AR-negative CRPC. Mechanistically, the m6A levels of mRNA, including NFIB and its E3 ubiquitin ligase TRIM8, were increased in AR-negative CRPC cells. Elevated m6A methylation of NFIB mRNA recruited YTHDF2 to increase mRNA stability and protein expression. Inversely, the m6A modification of TRIM8 mRNA, induced by ALKBH5 downregulation, decreased its translation and expression, which further promoted NFIB protein stability. Overall, this study reveals that upregulation of NFIB, mediated by m6A modification, triggers EMT and metastasis in AR-negative CRPC. Targeting the m6A/NFIB axis is a potential prevention and treatment strategy for AR-negative CRPC metastasis.Significance:NFIB upregulation mediated by increased m6A levels in AR-negative castration-resistant prostate cancer regulates transcription of EMT-related factors to promote metastasis, providing a potential therapeutic target to improve prostate cancer treatment.